Policy & Regulations

Mylan sells stake in Concord Biotech

December 8th, 2009|

World’s second-largest generic drug maker Mylan, which held a majority stake in Ahmedabad based Concord Biotech through its subsidiary


December 6th, 2009|

On Friday, shares of Cipla touched a 52-week high of Rs 360.80 on the BSE following its management saying early this week that the company is in talks with ‘multiple global companies’ for a drug research and supply agreement. The company has neither confirmed nor denied that it is talking to Pfizer, the world’s largest drugmaker, for an alliance on this front.

Avon to gain from nod to Ranbaxy’s drug

December 6th, 2009|

Ranbaxy Laboratories exclusive launch of generic anti-herpes Valtrex (valacyclovir hydrochloride) tablets in the US will help a listed Indian drug company, Hyderabad-based Avon Organics.

Cipla in talks with global cos for research agreement

December 3rd, 2009|

Mumbai-based drugmaker Cipla is in talks with global pharma majors for a drug research and supply agreement, said a top company executive recently.

NPPA revises prices of 119 formulation packs

November 20th, 2009|

The National Pharmaceutical Pricing Authority (NPPA) has newly fixed or revised prices of 119 formulation packs and issued corrigendum orders on two insulin formulation packs for which it has revised prices in March, 2009.

In healthcare, we can at best play catch-up with China

November 19th, 2009|

Dan Vasella, the chief executive of Swiss firm Novartis, which has been struggling for the last five years to secure the patent rights in India on Glivec, its therapy for a rare form of blood cancer called chronic myeloid leukemia, has spoken again on the alleged gaps in the Indian patent system.

Suven Life Sciences plans to raise funds for clinical trials

November 17th, 2009|

Suven Life Sciences Ltd, the Hyderabad-based biopharmaceutical company that is working on 10 new molecules for central nervous system (CNS) disorders or ailments, plans to raise funds for further trials on one of these, SUVN-502.

Medicis deal, generic biz to boost financials

November 16th, 2009|

Recent developments could well be a pointer to better days ahead for Glenmark Pharma which has had a relatively poor performance in the past four quarters.

BioInvent inks licensing pact with Daiichi Sankyo to discover & develop therapeutic antibodies

November 16th, 2009|

BioInvent International AB has entered into a licence and discovery agreement with Daiichi Sankyo Company, Limited for the development of therapeutic antibodies against multiple targets. Under the terms of the collaboration, Daiichi Sankyo will be granted broad access to BioInvent's discovery and development technology platform and in house antibody expertise. As part of the agreement, BioInvent has secured certain co-promotion rights in Scandinavia and the Baltic countries.

E7 the new El Dorado for pharma

November 11th, 2009|

When one door closes, another opens. What Alexander Graham Bell said ages ago makes perfect sense for the medicinemakers today. With developed markets, for long a lucrative source of revenue, crimped by slowdown, pharma firms are turning attention to the galloping seven in the developing world — Brazil, Russia, India, China (or the famed BRIC), and Mexico, Indonesia, and Turkey –or the E7 — as the new El Dorado.


November 9th, 2009|

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts.

US health bill to benefit local generic firms

November 9th, 2009|

The US healthcare bill, which has been passed by the US House of Representatives and is awaiting nod from the Senate, holds a lot of promise for generic manufacturers from India.

Biocon hums with plans, pitches for global top 3 slot

November 9th, 2009|

Biocon was scouting for more strategic alliances and exploring opportunities for outlicensing its biotech drugs under development, as it pitches for a slot among the top three bio-pharmaceutical players across the globe, said Kiran Mazumdar-Shaw, chairman and managing director.

ABLEs fourth biotech investor forum to start in Mumbai on Nov 5

November 2nd, 2009|

The fourth edition of the biotechnology investor forum, BioInvest 2009, organized by The Association of Biotechnology Led Entrepreneurs (ABLE) will be held in Mumbai on November 5. The event has been designed to ascertain the future of investment and partnerships in the country’s biosciences space.

Not the right medicine

November 2nd, 2009|

Govt can help by raising public spending on healthcareThe Indian Pharmaceutical Alliance, which represents a large section of the country’s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the industry, which has seen a string of foreign acquisitions of Indian players.

India, the land of rising opportunities for Japan

November 2nd, 2009|

India has become a major hub for pharmaceutical companies of the world. An India-strategy is a must for all western companies and is often mandated by their managements.

Cadila Pharma eyes Rs 80 crore from Risorine

November 1st, 2009|

Aims to enter China, Russia and African countriesAhmedabad-based pharma major Cadila Pharmaceuticals is betting big on the latest product from its stable, Risorine, a combination drug for treating tuberculosis, as it plans to take the drug to markets like China, Russia and African countries in the long run and also expects to multiply its turnover from the segment by over ten times in the coming two years.

Pharma Dept moots a string of measures to boost research in pharma industry

October 28th, 2009|

Pharmaceutical Department has recommended to the Department of Revenue a number of measures including hiking the benefit of weighted exemption to companies engaged in research and development with a view to scale up their overall spending in research activities in the country.

Avesthagen forms global Joint Venture with Limagrain in Atash Seeds Private Limited.

October 26th, 2009|

Novel seeds for the challenges of the changing environment.Today, India's leading life sciences company, Avesthagen Limited announced the formation of a joint venture (JV) “Atash Seeds Private Limited” with Limagrain, an international cooperative group.

Dr Reddys net rises 106 percent on cost cuts, higher sales

October 23rd, 2009|

Dr Reddy’s Laboratories, India’s second-largest drug maker by sales after Ranbaxy, maintained its revenue growth forecast at 10% for this fiscal, despite pricing pressures in Germany and a shrinking pharma market in Russia.